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Inﬂammatory cytokineInnate immune and inﬂammatory responses mediated by Toll like receptors (TLRs) have been implicated in
myocardial ischemia/reperfusion (I/R) injury. This study examined the role of TLR3 in myocardial injury induced
by twomodels, namely,myocardial infarction (MI) and I/R. First, we examined the role of TLR3 inMI. TLR3 deﬁcient
(TLR3−/−) and wild type (WT) mice were subjected to MI induced by permanent ligation of the left anterior
descending (LAD) coronary artery for 21 days. Cardiac function was measured by echocardiography. Next, we
examined whether TLR3 contributes to myocardial I/R injury. TLR3−/− andWTmice were subjected to myocardial
ischemia (45 min) followed by reperfusion for up to 3 days. Cardiac function and myocardial infarct size were
examined. We also examined the effect of TLR3 deﬁciency on I/R-induced myocardial apoptosis and inﬂammatory
cytokine production. TLR3−/−mice showed signiﬁcant attenuation of cardiac dysfunction afterMI or I/R.Myocardial
infarct size and myocardial apoptosis induced by I/R injury were signiﬁcantly attenuated in TLR3−/− mice. TLR3
deﬁciency increases B-cell lymphoma 2 (BCL2) levels and attenuates I/R-increased Fas, Fas ligand or CD95L
(FasL), Fas-Associated protein with Death Domain (FADD), Bax and Bak levels in the myocardium. TLR3 deﬁciency
also attenuates I/R-inducedmyocardial nuclear factor KappaB (NF-κB) binding activity, Tumor necrosis factor alpha
(TNF-α) and Interleukin-1 beta (IL-1β) production as well as I/R-induced inﬁltration of neutrophils and
macrophages into the myocardium. TLR3 plays an important role in myocardial injury induced by MI or I/R. The
mechanisms involve activation of apoptotic signaling and NF-κB binding activity. Modulation of TLR3 may be an
effective approach for ameliorating heart injury in heart attack patients.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Cardiovascular disease is the number one killer in the United States
[27]. Each year, an estimated 785,000 Americans will have a new
coronary attack, 470,000 will have a recurrent attack and 195,000
Americans will have silent myocardial infarctions [27]. Despite extensive
investigation, the cellular andmolecularmechanisms that are involved in
the initiation and progress of myocardial injury in response to ischemia/
reperfusion (I/R) are still unclear.
Innate immune and inﬂammatory responses mediated by Toll-
like receptors (TLRs) have been demonstrated to be involved in
the pathophysiology of myocardial I/R injury [3,23]. TLRs are pattern
recognition receptors that play an important role in the induction ofast Tennessee State University,
SA. Tel.: +1 423 439 6215;
ights reserved.innate immune and inﬂammatory responses [21,42]. TLR-mediated
signaling predominately activates nuclear factor KappaB (NF-κB)
which is an important transcription factor regulating the expression
of genes associated with innate immunity and inﬂammatory responses
aswell as cell growth, cell survival, and cell death [21,42].We andothers
have reported that TLR4 deﬁciency or modulation of TLR4 mediated
signaling decreases myocardial injury following I/R [1,3,4,13,17,23].
TLR3 is located in intracellular endosomes and recognizes double-
stranded RNA (dsRNA) and polyinosinic–polycytidylic acid (Poly I:C, a
synthetic analog of dsRNA), resulting in induction of antiviral immune
responses [20]. Recently, Cavassani et al. reported that TLR3 deﬁcient
(TLR3−/−) mice showed an increased survival rate in cecal ligation
and puncture induced sepsis [2]. We have shown that TLR3−/− mice
exhibit protection against polymicrobial sepsis-induced cardiac dys-
function [10]. These data suggest that TLR3 plays an important role in
cardiac function during sepsis. However, whether TLR3 contributes to
myocardial injury induced by myocardial infarction or I/R has not
been investigated. It is possible that TLR3 plays a role in myocardial
ischemic injury by recognition of endogenous ligands, i.e. damage-
23C. Lu et al. / Biochimica et Biophysica Acta 1842 (2014) 22–31associated molecular patterns (DAMPs) that are released during myo-
cardial I/R injury.
We hypothesized that TLR3 contributes to myocardial injury by
recognition of DAMPs duringmyocardial I/R. To evaluate our hypothesis,
we examined the role of TLR3 in myocardial injury induced by either
permanent ligation-induced myocardial infarction (MI) or ischemia/
reperfusion (I/R) using TLR3 deﬁcient (TLR3−/−) mice. We observed
that TLR3 deﬁciency signiﬁcantly attenuates myocardial dysfunction
induced by both models, i.e. MI and I/R. TLR3 deﬁciency also reduces
infarct size and myocardial apoptosis after I/R injury. Our data indicate
that TLR3 plays an important role in myocardial ischemic and I/R injury.2. Materials and methods
2.1. Animals
TLR3 knockout mice (TLR3−/−) and wild type (WT) genetic
background control mice (C57BL/6) were obtained from Jackson
Laboratory (Indianapolis, IN) [10]. The mice were maintained in
the Division of Laboratory Animal Resources at East Tennessee
State University (ETSU). The experiments outlined in this article
conform to the Guide for the Care and Use of Laboratory Animals
published by the National Institutes of Health (NIH Publication,
8th Edition, 2011). All aspects of the animal care and experimental
protocols were approved by the ETSU Committee on Animal Care.2.2. Models of myocardial infarction (MI) and ischemia/reperfusion
(I/R) injury
Myocardial infarction was induced by permanent ligation of the left
anterior descending (LAD) coronary artery as described previously [18].
Myocardial I/R injury was induced as described previously [11,13,
17,38]. Brieﬂy, TLR3−/− and age-matched WT male mice (26–28 g
body weight) were anesthetized by 5.0% isoﬂurane inhalation,
intubated and ventilated with room air using a rodent ventilator.
Anesthesia was maintained by inhalation of 1.5% isoﬂurane driven
by 100% oxygen ﬂow. Body temperature was regulated at 37 °C by
surface water heating. Following the skin incision, the hearts were
exposed through a left thoracotomy in the fourth intercostal space.
For induction of MI, the LAD coronary artery was permanently
ligated with 8-0 silk ligature [18]. For induction of I/R injury, the
LAD coronary artery was ligated with 8-0 silk ligature that was tied
using a ‘shoestring knot’ over a 1 mm polyethylene tube (PE-10).
After completion of 45 min of occlusion, the coronary artery was
reperfused by pulling on the exteriorized suture to release the
knot. Cardiac function was measured by echocardiography [26,38].
After completion of the experiments, the mice were euthanized by
CO2 inhalation and the hearts were harvested.2.3. Evaluation of myocardial infarct size
Myocardial infarct size was evaluated by triphenyltetrazolium
chloride (TTC, Sigma-Aldrich) staining as described previously
[11,13,17,38]. Brieﬂy, the hearts were perfused with saline on a
Langendorff system to wash blood from the coronary vasculature.
The LAD coronary artery was re-ligated at the previous site of
ligation prior to staining with 1% Evans Blue in order to assess area
at risk. Each heart was then sliced horizontally to yield ﬁve slices.
The slices were incubated in 1% TTC for 15 min at 37 °C, ﬁxed by
immersion in 10% neutral buffered formalin. The area of infarction
on both sides of each slice was determined by an image analyzer,
corrected for the weight of each slice, and summed for each heart.
Ratios of risk area vs. left ventricle area (RA/LV) and infarct area
vs. risk area (IA/RA) were calculated and expressed as a percentage.2.4. Echocardiography
Transthoracic two-dimensionalM-mode echocardiogramand pulsed
wave Doppler spectral tracings were obtained using a Toshiba Aplio 80
Imaging System (Toshiba Medical Systems, Tochigi, Japan) equipped
with a 12-MHz linear transducer as described previously [26,38].
Percent fractional shortening (%FS) and percent ejection fraction (%EF)
were calculated as described previously [26,38]. All measurements
were made by one observer who was blinded with respect to the
identity of the tracings. All data were collected from 10 cardiac cycles.2.5. Western blot
Western blots were performed as described previously [11,13,17,38].
Brieﬂy, the cellular proteins were separated by SDS-polyacrylamide gel
electrophoresis, transferred onto Hybond ECL membranes (Amersham
Pharmacia, Piscataway, NJ). The membranes were incubated with ap-
propriate primary antibody anti-Fas (CD95), anti-FasL, anti-FADD, anti-
vascular cell adhesion molecule-1 (VCAM-1), anti-intercellular adhesion
molecule-1 (ICAM-1), anti-Bcl-2, anti-Bax, and anti-Bak (Santa Cruz
Biotechnology Inc., Santa Cruz, CA), and anti-phospho-IκBα (Cell
Signaling Technology, Inc., Danvers, MA), respectively, followed by
incubationwith peroxidase-conjugated second antibodies (Cell Signaling
Technology) and analysis by the ECL system (Amersham Pharmacia,
Piscataway, NJ). To control for lane loading, the same membranes were
probed with anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase,
Biodesign, Saco, Maine) after being washed with stripping buffer. The
signals were quantiﬁed using the Syngene G: BOX gel imaging system
(Syngene, USA, Frederick, MD).2.6. In situ apoptosis assay
Myocardial apoptosis was examined as described previously [11,13,
17,38] using the In Situ Cell Death Detection Kit, Fluorescein (Roche,
USA). Brieﬂy, the hearts were harvested and sliced cut horizontally.
One slice was immersion-ﬁxed in 4% buffered paraformaldehyde,
embedded in parafﬁn and cut at 5μmthick. The sectionswere incubated
with the commercially prepared labeling mixture supplied by the
manufacturer at 37 °C for 1 h. Nuclei of living and apoptotic cells were
counterstained with Hoechst 33342 (Invitrogen). Three slides from
each block were evaluated for percentage of apoptotic cells and four
ﬁelds on each slide were examined at the border areas using a deﬁned
rectangular ﬁeld areawith 20×magniﬁcation. The numbers of apoptotic
cardiac myocytes are presented as a percentage of total cells counted.2.7. Caspase-activity
Caspase-3/7 and -8 activities in heart tissues were measured as
described previously [19] using a Caspase-Glo assay kit (Promega).2.8. Electrophoretic mobility shift assay (EMSA)
Nuclear proteins were isolated from heart samples as previously
described [11,13,17,38] and NF-κB binding activity was measured using
a LightShift Chemiluminescent EMSA kit (Thermo Fisher Scientiﬁc,
Waltham, MA) according to the instructions of the manufacturer.2.9. ELISA quantiﬁcation of cytokines
The levels of inﬂammatory cytokines (TNF-α and IL-1β) in the serum
were assessed by ELISA (PeproTech, Rocky Hill, NJ) according to the
instructions provided by the manufacturer [10,24,38].
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Immunohistochemistry was performed as described previously
[10,38]. Brieﬂy, the heart tissues were immersion-ﬁxed in 4% buffered
paraformaldehyde, embedded in parafﬁn, and cut at 5 μm sections.
The sectionswere stainedwith speciﬁc goat anti-ICAM-1 (1:50 dilution,
Santa Cruz Biotechnology Inc.) and rabbit anti-VCAM-1 (1:50 dilution,
Santa Cruz Biotechnology Inc.), and treated with the ABC staining
system (Santa Cruz Biotechnology Inc.) according to the instructions
of the manufacturer. Three slides from each block were evaluated,
counterstained with hematoxylin, and examined with brightﬁeld
microscopy. Four different areas of each section were evaluated.
2.11. Accumulation of neutrophils and macrophages
Neutrophil accumulation in the heart tissues was examined by
staining with naphtol AS-D chloroacetate esterase (Sigma-Aldrich,
St. Louis, MO) as described previously [10,38]. Macrophages in the
myocardium were examined with the macrophage speciﬁc antibody
F4/80 (1:50 dilution, Santa Cruz Biotechnology Inc., CA). Three slides
from each block were evaluated, counterstained with hematoxylin,
and examined with brightﬁeld microscopy. Four different areas of
each section were evaluated. The results are expressed as the numbers
of macrophages/ﬁeld (40×).
2.12. Statistical analysis
All data were expressed as mean ± SEM. Comparisons of data
between groups were made using one-way analysis of variance
(ANOVA) and Tukey's procedure for multiple range tests was
performed. p b0.05 was considered to be signiﬁcant.
3. Results
3.1. TLR3 deﬁciency attenuates cardiac dysfunction induced by myocardial
infarction
To investigate whether TLR3 plays a role in cardiac dysfunction
following myocardial infarction, we performed permanent ligation of
LAD coronary artery in TLR3−/− and WT mice and measured cardiac
function before and 3, 7, 14 and 21 days after induction of myocardial
infarction. As shown in Fig. 1A, ejection fraction (%EF) and fractional
shortening (%FS) values were signiﬁcantly reduced, compared with
baseline, in WT and TLR3−/− mice following permanent ligation. The
%EF and %FS in TLR3−/− and WT mice decreased as a function of time.
However, TLR3 deﬁciency resulted in signiﬁcantly greater attenuation
of cardiac dysfunction after myocardial infarction. There was no sig-
niﬁcant difference in %EF and %FS of baseline between TLR3−/− and
WTmice. Thedata indicates that TLR3 contributes to cardiac dysfunction
following induction of myocardial infarction.
3.2. TLR3 deﬁciency attenuates cardiac dysfunction following transient
myocardial ischemia followed by reperfusion
Next, we examined the role of TLR3 in cardiac function following
myocardial I/R injury. TLR3−/− and WT mice were subjected to
myocardial ischemia (45 min) followed by reperfusion for up to
3 days. Cardiac function was assessed by echocardiography before
and after reperfusion for 1 and 3 days. Fig. 1B showed that %EF and
%FS in WT and TLR3−/−mice were signiﬁcantly decreased following
myocardial I/R injury compared with the baseline. However, TLR3
deﬁciency markedly attenuated I/R-induced cardiac dysfunction.
The %EF and %FS values in TLR3−/− mice were signiﬁcantly greater on
day 1 (45.1% and 52.7%) and on day 3 (39.7% and 42.3%) after
reperfusion than in WT I/R mice, respectively. The data further conﬁrm
that TLR3 contributes to cardiac dysfunction in myocardial I/R injury.3.3. TLR3 deﬁciency reducesmyocardial infarct size followingmyocardial I/R
injury
Wealso examined the role of TLR3 inmyocardial infarct size following
I/R. TLR3−/− and WT mice were subjected to myocardial ischemia
(45 min) followed by reperfusion (4 h). The hearts were harvested for
the evaluation of infarct size. As shown in Fig. 1C, ischemia followed by
reperfusion induced signiﬁcant myocardial injury as denoted by the
infarct size inWTmice. In contrast, infarct size was signiﬁcantly reduced
(42.9%) in TLR3−/− mice following I/R, when compared with WT mice.
There was no signiﬁcant difference in the ratio of risk area/left ventricle
(RA/LV), which reﬂects the position of the coronary artery ligation,
between TLR3−/− and WT mice.
3.4. TLR3 deﬁciency attenuates I/R-induced myocardial apoptosis
Cardiacmyocyte apoptosis contributes to myocardial I/R injury [36].
We examined whether TLR3 deﬁciency will attenuate myocardial
apoptosis following I/R injury. Fig. 2A shows that I/R signiﬁcantly
increased the TUNEL positive apoptotic cells by 9.1 fold in the WT
myocardium compared with WT sham control. I/R also induced
myocardial apoptosis in TLR3−/− mice by 5.2 fold, when compared
with TLR3−/− sham control mice. However, myocardial apoptotic cells
in TLR3−/− I/R mice were markedly reduced by 41.1% compared with
WT I/R mice.
Caspase-3 and -8 activities are the speciﬁc markers for apoptosis.
As shown in Fig. 2B, I/R signiﬁcantly induced caspase-3/7 activity by
51.1% and caspase-8 by 45%, in the WT I/R myocardium, when
compared with sham control. In contrast, TLR3−/− mice showed a
signiﬁcant attenuation of I/R-induced caspase-3/7 and caspase-8
activities following myocardial I/R injury. The levels of caspase-3/7
and caspase-8 activities in TLR3−/− I/R mice were reduced by16.4%
and 16.6% (p b0.05) when compared with WT I/R mice.
3.5. TLR3 deﬁciency attenuates up regulation of pro-apoptotic factors in the
myocardium
Activation of Fas/FasL mediated apoptotic signaling plays a role
in I/R-induced myocardial apoptosis [36]. Bax and Bak1 are pro-
apoptotic mediators [36]. We examined the effect of TLR3 deﬁciency
on I/R-induced activation of Fas/FasL-mediated extrinsic apoptotic
signaling in the myocardium. Fig. 3A–C shows that I/R signiﬁcantly
increased the levels of Fas, FasL and FADD, respectively in the WT
myocardium when compared with WT sham control. In contrast,
TLR3 deﬁciency markedly attenuated I/R-induced increases in the
levels of Fas by 27.2% and prevented I/R-increased FasL and FADD,
compared with WT I/R mice.
We also examined the effect of TLR3 deﬁciency on I/R-induced
activation of intrinsic apoptotic signaling in the myocardium. In intrinsic
apoptotic signaling, Bcl-2 is an important anti-apoptotic factor while Bak
and Bax are pro-apoptotic mediators [36]. Fig. 3D–F shows that I/R
markedly increased the levels of Bax (↑52.6%) and Bak (↑52.9%) and
decreased the levels of Bcl2 in the myocardium compared with sham
control. In contrast, TLR3 deﬁciency prevented I/R increases in the levels
of Bax and Bak, when comparedwithWT I/Rmice. Importantly, TLR3−/−
completely prevented the deleterious effect of I/R on myocardial Bcl2
levels. In addition, the levels of Bcl2 in TLR3−/− sham mice were
signiﬁcantly greater than in WT sham mice.
3.6. TLR3 deﬁciency prevents I/R-induced myocardial NF-κB binding
activity and systemic TNF-α and IL-1β production
We have previously reported that I/R signiﬁcantly induced
myocardial NF-κB binding activity [12,13,16,17]. Inhibition of NF-κB
activity has been shown to attenuate myocardial injury following I/R
[22,29]. We determine the whether TLR3 deﬁciency will attenuate I/R-
Fig. 1. TLR3 deﬁciency attenuates cardiac dysfunction followingmyocardial infarction or I/R injury and decreasesmyocardial infarct size followingmyocardial I/R injury. TLR3−/− and age-
matchedWTmicewere subjected tomyocardial infarction (MI) by permanent ligation of LAD coronary artery (A) ormyocardial ischemia (45min) followed by reperfusion for up to 3days
(B). Cardiac function was measured by echocardiography before (baseline) and after ischemia/reperfusion. (C) TLR3 deﬁciency decreases myocardial infarct size. TLR3−/− and age-
matched WT mice were subjected to myocardial ischemia (45 min) followed by reperfusion (4 h). Infarct size was determined by TTC staining. Blue color shows non-ischemic areas,
red color indicates ischemic areas. Pale (white) indicates necrotic tissues. Ratios of risk area vs. left ventricle area (RA/LV) and infarct area vs. risk area (IA/RA) were calculated and are
presented in the graphs. Photographs of representative heart sections are shown above. There were 8 mice in each group. *p b 0.05 compared with indicated groups. #p b 0.05 compared
with respective baseline.
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induced NF-κB binding activity by 1.76 fold in WT mice compared
with sham control. TLR3 deﬁciency prevented I/R-induced NF-κB
binding activity in the myocardium. Activation of NF-κB stimulates the
expression of numerous genes, including pro-inﬂammatory cytokines
[21,42]. Fig. 4B shows that circulating levels of TNFα and IL-1β were
markedly increased by 1.2 fold and 2.6 fold, respectively, following
myocardial I/R compared with sham control. However, TLR3 deﬁciency
attenuated I/R-induced increases in the production of TNFα and IL-1β in
the serum.3.7. TLR3 deﬁciency attenuates I/R-induced inﬁltration of neutrophils and
macrophages into the myocardium
Inﬁltration of neutrophils and macrophages into the myocardium
plays an important role in cardiac dysfunction and myocardial I/R injury
[7,14]. We examined the effect of TLR3 deﬁciency on the inﬁltration of
neutrophils andmacrophages into themyocardium followingmyocardial
I/R injury. Fig. 5A shows that I/R increased the number of neutrophils in
the WT myocardium by 20 fold on day 1 and by 30 fold on day 3 after
reperfusion, when compared with sham control. I/R also induced the
Fig. 2. TLR3 deﬁciency attenuates I/R-inducedmyocardial apoptosis. TLR3−/− andWTmicewere subjected tomyocardial ischemia (45min) followed by reperfusion (24h). Sham surgical
operation served as sham control.Myocardial apoptosiswas examined by the TUNEL assay in the heart sections. (A) DAPI stained nuclei are blue color and TUNEL positive cells showgreen
ﬂuorescence. The bar graph shows the percent of apoptotic cells. n=3 in each group. (B) TLR3 deﬁciency prevents I/R-induced activity of caspase-3/7 and caspase-8 in themyocardium.
There were 6 mice in each group. *p b 0.05 compared with indicated groups.
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compared with sham control. However, the numbers of neutrophils in
the myocardium of TLR3−/− I/R mice were markedly reduced by 53.3%
on day 1 and by 38.8% on day 3 after reperfusion compared with WT I/R
mice. Fig. 5B shows that the numbers of positively staining macrophages
weremarkedly increased in theWTmyocardium by 8.6 fold on day 1 and
by 15 fold on day 3 after reperfusion compared with sham control.
In contrast, I/R induced inﬁltration of macrophages into the myocardium
in TLR3−/−mice was signiﬁcantly reduced, when compared withWT I/R
mice.3.8. TLR3 deﬁciency attenuates I/R-induced expression of adhesionmolecules
in the myocardium
Increased expression of adhesion molecules, such as VCAM-1 and
ICAM-1, promotes neutrophil and macrophage inﬁltration into the
myocardium during myocardial I/R injury [8,9]. We examined the role
of TLR3 deﬁciency in I/R-induced expression of adhesion molecules in
the myocardium. As shown in Fig. 5C, I/R signiﬁcantly increased the
levels of VCAM-1 by 57.8% and ICAM-1 by 118.7% in the myocardium
of WT mice compared with sham control. Immunohistochemistry also
Fig. 3. TLR3 deﬁciency attenuates I/R-increased FasL, Fas, FADD, Bak, and Bax expressions, and prevents I/R-induced decreases in myocardial Bcl-2 levels. TLR3−/− and WT mice were
subjected to myocardial ischemia (45 min) followed by reperfusion (24 h). Sham surgical operation serves as sham control. TLR3 deﬁciency attenuates I/R-increased levels of Fas (A),
FasL (B), FADD (C), Bak (D), and Bax (E) in the myocardium. (F) TLR3 deﬁciency increases the levels of Bcl2 in the myocardium following myocardial I/R. There were 6 mice in each
group. *p b 0.05 compared with indicated groups.
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tissues of WT I/R mice (Fig. 5D). In contrast, TLR3 deﬁciency attenuated
the I/R-increased levels of VCAM-1 by 40.7% and ICAM-1 by 31.4%,
compared with WT I/R mice. Immunohistochemistry showed that
there was less staining of VCAM and ICAM-1 in the heart tissues of
TLR3−/− I/R mice.
4. Discussion
The present study demonstrates that TLR3 contributes to
myocardial injury induced by either permanent ligation-induced
myocardial infarction (MI) or myocardial I/R. Speciﬁcally, we observed
that TLR3−/−mice showed signiﬁcantly attenuated cardiac dysfunction
following either permanent ligation of the LAD coronary artery or
transient ischemia followed by reperfusion. Myocardial I/R-induced
infarct size observed in WT mice was also signiﬁcantly reduced in
TLR3−/− mice. In addition, TLR3 deﬁciency attenuated I/R-induced
myocardial apoptosis, prevented I/R-induced NF-κB binding activity,
and sequestration of inﬂammatory cells into the myocardium. The datasuggest that TLR3 plays an important role in myocardial I/R injury
through activation of apoptotic signaling, stimulation of inﬂammatory
responses, and promotion of inﬂammatory cell inﬁltration into
the myocardium. Thus, TLR3 may be an important target for the
management and treatment of myocardial I/R injury.
TLR3 recognizes viral double-stranded RNA (dsRNA) and induces
antiviral immune responses [20]. Our data show that TLR3 deﬁciency
attenuates myocardial injury in response to I/R, suggesting that TLR3
may recognize endogenous ligands during myocardial I/R. At present
we do not fully understand the nature of the endogenous ligands or
DAMPs that activate TLR3 during myocardial I/R injury. Recently,
Cavassani et al. [2] have demonstrated that TLR3 serves as an
endogenous sensor that recognizes RNA released from necrotic
cells, resulting in ampliﬁcation of inﬂammation in experimental
polymicrobial peritonitis and ischemic gut injury. Interestingly,
recent studies have shown that TLRs serve as microRNA receptors
[5,6]. MicroRNAs (miRs) are 21 to 23 nucleotide non-protein-coding
RNA molecules, which have been identiﬁed as novel regulators of
gene expression at the post-transcriptional level by binding to target
Fig. 4. TLR3-deﬁciency prevents I/R-induced myocardial NF-κB binding activity and pro-
inﬂammatory cytokine production in the circulation. TLR3−/− and WT mice were
subjected to myocardial ischemia (45min) followed by reperfusion (24 h). Sham surgical
operation serves as sham control. The hearts were harvested for the preparation of the
nuclear and cytoplasmic proteins. TLR3 deﬁciency prevents I/R-induced NF-κB binding
activity (A), TNF-α (B), and IL-1β (C) production. There were 6 mice in each group.
*p b 0.05 compared with indicated groups.
28 C. Lu et al. / Biochimica et Biophysica Acta 1842 (2014) 22–31messenger RNAs (mRNAs) [30,32]. Recent data indicates that
several miRs are involved in ischemic heart disease [25,28,39].
Whether TLR3 is involved in the recognition of the increased
miRs, resulting in ampliﬁcation of inﬂammation during myocardial
I/R has not been established.
We have observed that TLR3 deﬁciency signiﬁcantly attenuated
cardiac dysfunction following either myocardial infarction induced by
permanent ligation of LAD coronary artery or transient ischemia followed
by reperfusion. Since transient ischemia followed by reperfusion injury isthemost common clinical presentation amongpatientswith heart attack,
we employed the I/R model of myocardial injury for the subsequent
mechanistic studies.
TLR3 mediates signaling via TIR/TRIF which interacts with either
1) RIP1/Peli1 to activate TRAF6, leading to NF-κB activation and nuclear
translocation; 2) RIP1/RIP3 to stimulate FADD-dependent apoptotic
signaling; and 3) TRAF3/TBK1 to activate IRF3/7, resulting in stimulating
interferon production [41]. At the present, the role of IRF3-mediated
signaling in myocardial I/R injury is unclear. Yang et al. reported that
HMGB1 mediates brain I/R injury via TRIF adaptor independent TLR4
signaling [40]. Since TRIF is an important component of TLR3-
mediated signaling [41], the data indicates that TLR3/TRIF signaling
may contribute to brain ischemic injury. On the other hand, recent
studies have shown that IRF3-mediated signaling may contribute to
preconditioning induced protection against cerebral I/R injury [34].
For example, Stevens et al. reported that multiple preconditioning
paradigms converge on IRF3/7 dependent signaling to promote
tolerance to ischemic brain injury [33].
TLR3 also mediates activation of NF-κB which is an important
transcription factor controlling innate immune and inﬂammatory
cytokine gene expression [21,42]. Activation of NF-κB contributes to
myocardial I/R injury [22,29]. We have previously reported that I/R
signiﬁcantly increased the levels of TLR4-mediated MyD88-dependent
NF-κB activation in the myocardium [12,13,16,17]. In the present
study, we observed that I/R markedly induced NF-κB activation in WT
mice but not in TLR3 deﬁcient mice, suggesting that TLR3 plays a role
in the induction of myocardial NF-κB nuclear translocation and binding
activity during myocardial I/R injury. TLR3 is located in intracellular
endosomes and recognizes double stranded RNA and poly I:C, a
synthetic analog of dsRNA and byproducts from apoptotic and necrotic
cells [2,15,31]. The TLR3-mediated signaling pathway predominately
activates IRF3 and NF-κB through TRIF-dependent pathways [21,42].
Activation of these pathways results in the expression of various
inﬂammatory cytokines including TNFα, IL-1β and IL-6 as well as IFNs
[21,42]. It is possible that I/R results in the production of endogenous
ligands, i.e. disease associated molecular patterns which are recognized
by TLR3, leading to NF-κB and subsequent inﬂammatory cytokine
production. Indeed, we have observed that TLR3 deﬁciency markedly
attenuated I/R-increased inﬂammatory cytokine production in the
circulation.
The inﬁltration of neutrophils andmacrophages into themyocardium
plays an important role in mediating cardiac dysfunction following
myocardial I/R injury [7,14]. Recent studies have shown that ischemia
induces rapid recruitment of circulating macrophages into the
myocardium [7,14]. These recruited inﬂammatory cells release
inﬂammatory cytokines and chemokines which further attract
neutrophil inﬁltration and promote inﬂammatory responses [8,9].
We have observed in the present study that TLR3 deﬁciency
signiﬁcantly attenuated I/R-induced inﬁltration of macrophages
and neutrophils into the myocardium which were observed in the
myocardium of WT I/R mice. These results positively correlated
with I/R-induced increases in the expression of adhesion molecules,
such as ICAM-1 and VCAM-1. However, adhesion molecule ex-
pression in the myocardium was signiﬁcantly attenuated by TLR3
deﬁciency. It has been well documented that activation of NF-κB
regulates the expression of inﬂammatory cytokines and chemokines
during myocardial I/R. Therefore, it is possible that TLR3 deﬁciency
attenuated I/R-induced inﬁltration of inﬂammatory cells into the
myocardium by preventing I/R-induced NF-κB binding activity.
It has been well demonstrated that cardiac myocyte apoptosis
contributes to myocardial I/R injury [36]. We have observed that TLR3
deﬁciency signiﬁcantly attenuated I/R-induced myocardial apoptosis.
The mechanisms by which TLR3 deﬁciency attenuated I/R-induced
myocardial apoptosis involve attenuation of Fas/FasL-mediated apo-
ptotic signaling in the myocardium following I/R. In addition, TLR3
deﬁciency also prevented I/R-induced Bax and Bak expressions and
29C. Lu et al. / Biochimica et Biophysica Acta 1842 (2014) 22–31increased Bcl2 levels in the myocardium. Bax acts as an antagonist
against anti-apoptotic Bcl2, while Bak-1 is the pro-apoptotic mito-
chondrial membrane protein. When Bcl2 is decreased and Bak-1 is
oligomerized, it increases mitochondrial membrane permeability and
promotes the release of cytochrome c [37,43]. Our data suggest that
TLR3 contributes to I/R-induced myocardial apoptosis via activation of
both extrinsic and intrinsic apoptotic signaling pathways. At present,
we do not fully understand the mechanisms by which TLR3 activates
apoptotic signaling during myocardial I/R injury. However, recentFig. 5. TLR3 deﬁciency attenuates I/R-induced inﬁltration of neutrophils and macrophages into
followed by reperfusion for indicated time. Sham surgical operation served as sham control. (A)
myocardium. The pink color indicates positive neutrophils in the myocardium (A). The dark
deﬁciency prevents I/R-induced increases in the expression of VCAM-1 (C) and ICAM-1 (D) in
in the myocardium. There were 6 mice in each group. *p b 0.05 compared with indicated groupstudies have shown that TLR3-mediated cell death is involved in the
engagement of both extrinsic and intrinsic apoptotic pathways [35].
Sun et al. reported that treatment of endothelial cells with the TLR3
agonist, poly I:C up-regulated the p53 family member,TAp63α, and
initiated both intrinsic and extrinsic apoptotic pathways in a caspase-
dependent manner leading to cell death [35]. The authors proposed
that activation of TLR3 by either endogenous dsRNA or exogenous
poly I:C induced the up-regulation of TAp63α, which translocated into
the nucleus and bound to p53- or p63-responsive elements to up-the myocardium. TLR3−/− and WTmice were subjected to myocardial ischemia (45min)
TLR3 deﬁciency decreases the inﬁltration of neutrophils (A) andmacrophages (B) into the
brown color indicates positive macrophages (B). There were 3 mice in each group. TLR3
the myocardium. The dark brown color indicates positive staining of VCAM-1 or ICAM-1
s.
Fig. 5 (continued).
30 C. Lu et al. / Biochimica et Biophysica Acta 1842 (2014) 22–31regulate the expression of Noxa, the pro-apoptotic Bcl-2 familymember
and down-regulate anti-apoptotic Bcl-2 [35]. TAp63α also up-regulated
the expression of TRAIL and its receptors, DR4 and DR5. The interaction
of TRAILwith DR4/5 activates caspase-8, resulting in the initiation of theextrinsic apoptotic signaling pathway [35]. Collectively, TLR3 may be a
target for preventing I/R-induced myocardial apoptosis.
In summary, the present study demonstrated that TLR3 deﬁciency
attenuates cardiac dysfunction induced by MI or I/R. TLR3−/− mice
31C. Lu et al. / Biochimica et Biophysica Acta 1842 (2014) 22–31showed a signiﬁcantly reduced myocardial infarct size following I/R
injury. Themechanisms involve the inhibition of I/R-activated apoptotic
signaling and prevention of I/R-induced NF-κB binding activity,
resulting in attenuation of I/R-induced inﬁltration of inﬂammatory
cells into the myocardium. TLR3 may be an attractive target for the
treatment and management of ischemic heart disease.
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